Checkpoint inhibition • Trial suspension • Tumor mutational burden • IO biomarker • Checkpoint block
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • TERT mutation • IDH wild-type • TERT promoter mutation
|
FoundationOne® CDx
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)